Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Key Points

• Teva Pharmaceutical Industries experienced an unusual spike in options trading, with investors purchasing 51,020 call options—an increase of about 90% over the typical daily volume.
• The company's stock rose to $20.15 during trading, significantly above its 52-week low of $12.47 and nearing its high of $22.80.
• Wall Street analysts have upgraded their outlook on Teva, with the firm receiving several "buy" ratings and an average price target of $25.14 from various investment firms.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) saw some unusual options trading on Tuesday. Investors purchased 51,020 call options on the stock. This is an increase of approximately 90% compared to the typical daily volume of 26,892 call options.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded up $0.97 during mid-day trading on Tuesday, hitting $20.15. The stock had a trading volume of 19,930,463 shares, compared to its average volume of 11,939,255. The firm has a market cap of $23.11 billion, a P/E ratio of -125.94, a PEG ratio of 1.07 and a beta of 0.72. The business has a fifty day moving average price of $17.83 and a 200-day moving average price of $16.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's revenue was up .3% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Finally, The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $25.14.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently made changes to their positions in the company. Duquesne Family Office LLC raised its stake in shares of Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after buying an additional 5,882,350 shares during the period. Amundi raised its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after purchasing an additional 105,846 shares during the period. IFM Investors Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 9.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock valued at $3,797,000 after purchasing an additional 19,447 shares during the period. Jump Financial LLC raised its stake in shares of Teva Pharmaceutical Industries by 172.1% during the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after purchasing an additional 838,423 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 5.7% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock valued at $38,487,000 after purchasing an additional 134,705 shares during the period. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.